[18F] fluoroestradiol (FES) PET as a predictive measure for endocrine therapy in women with newly diagnosed metastatic breast cancer

被引：0
|
作者：
Linden, Hannah
Clark, Amy
Fowler, Amy
Novakova, Alena
Mankoff, David
Dehdashti, Farrokh
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Wisconsin, Madison, WI 53706 USA
[4] Washington Univ, St Louis, MO 63130 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-06-04
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity.
    Peterson, Lanell M.
    Kurland, Brenda F.
    Novakova, Alena
    Lee, Jean H.
    Specht, Jennifer M.
    Muzi, Mark
    Romine, Perrin
    Wu, Vicky
    Mankoff, David A.
    Kinahan, Paul
    Linden, Hannah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] The role of PET imaging with [18F]16α-fluoro-17β-fluoroestradiol in predicting response to endocrine therapies in patients with breast cancer
    DiGregorio, Nicholas
    Brand, Christine
    Dunham, Dustin
    McManus, Eleanor
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[18F]fluoroestradiol ([18F]FES)for human breast cancer imaging
    Wang, Min
    Glick-Wilson, Barbara E.
    Zheng, Qi-Huang
    APPLIED RADIATION AND ISOTOPES, 2020, 160 (160)
  • [24] Automated production of 16α-[18F]fluoroestradiol for breast cancer imaging
    Römer, J
    Füchtner, F
    Steinbach, J
    Johanssen, B
    NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (04) : 473 - 479
  • [25] Utility of 18F FDG-PET/CT for systemic staging assessment of newly diagnosed breast cancer
    Xing, W.
    Li, Q.
    Sun, Y.
    Chen, B.
    Tian, F.
    BREAST, 2019, 44 : S103 - S103
  • [26] Comparison of whole-body PET/CT and dedicated breast PET with F-18 Fluoroestradiol for breast cancer detection in patients with newly diagnosed ER-positive breast cancer
    Miyake, K.
    Takada, M.
    Shimizu, Y.
    Yuge, S.
    Kitano, Y.
    Ishimori, T.
    Kataoka, M.
    Kawashima, M.
    Kawaguchi, K.
    Oishi, T.
    Itagaki, K.
    Yamada, Y.
    Takeuchi, Y.
    Toi, M.
    Nakamoto, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S480 - S480
  • [27] Predictive value of (16 alpha[18-F]-fluoroestradiol) FES-PET in recurrent estrogen receptor positive (ER plus ) breast cancer
    Roy, Felix-Nicolas
    Croteau, Etienne
    Ouellet, Rene
    Bujold, Rachel
    Forget, Andre
    Dufresne, Jean
    van Lier, Johannes
    Benard, Francois
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [28] Early results of an NCI-sponsored Phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer (MBC)
    Peterson, Lanell
    Kurland, Brenda
    Linden, Hannah
    Link, Jeanne
    Schubert, Erin
    Gadi, Vijayakrishna
    Specht, Jennifer
    Eary, Janet
    Shankar, Lalitha
    Mankoff, David
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [29] [18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis
    Xu, Ying
    Yao, Ru
    Hao, Zhixin
    Chen, Fangyuan
    Liu, Bowen
    Sun, Qiang
    Pan, Bo
    Huo, Li
    Zhou, Yidong
    EJNMMI RESEARCH, 2025, 15 (01):
  • [30] Discrepancy between [18F]-FES and [18F]-FDG PET/CT in ER-positive breast cancer with oesophageal metastasis
    Peerapon Kiatkittikul
    Chetsadaporn Promteangtrong
    Anchisa Kunawudhi
    Dheeratama Siripongsatian
    Chanisa Chotipanich
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3297 - 3298
12345